Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia

Overview of attention for article published in Cancer Chemotherapy and Pharmacology, August 2012

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (76th percentile)
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

patent: 4 patents

Citations

dimensions_citation: 60 Dimensions

Readers on

mendeley: 54 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 4 patents that reference this research output.

Methods of detecting and treating pulmonary hypertension

Grant US-11927594-B2

United States of America

Methods of treatment using N-(3-fluorophenyl)-2-{3-[(7-{3-[ethyl(2-hydroxyethyl)amino]propo…

Grant US-9567358-B2

United States of America

METHOD OF TESTING SYSTEMIC RELEASE OF AZD1152 HQPA OR BIOEQUIVALENTS

Application WO-2016059149-A1

World Intellectual Property Organisation (WIPO)

Phosphonoxy quinazoline derivatives and their pharmaceutical use

Grant US-9018191-B2

United States of America